Osilodrostat oral tablets for adults with Cushing’s disease

References

• Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–1540.
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593–5602.
   PubMed Web of Science ®Google Scholar
• Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94:3121–3131.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Biller BMK, and Findling JW, et al. Treatment of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807–2831.
   PubMed Web of Science ®Google Scholar
• Bertagna X. MANAGEMENT OF ENDOCRINE DISEASE: can we cure Cushing’s disease? A personal view. Eur J Endocrinol. 2018;178:R183–200.
   PubMed Web of Science ®Google Scholar
• Reincke M, Ritzel K, Oßwald A, et al. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing’s syndrome. Eur J Endocrinol. 2015;173:M23–32.
   PubMed Web of Science ®Google Scholar
• Biller BMK, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454–2462.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease. Pituitary. 2016;19:138–148.
   PubMed Web of Science ®Google Scholar
• Tritos NA. Adrenally directed medical therapies for cushing syndrome. J Clin Endocrinol Metab. 2021;106:16–25.
   PubMed Web of Science ®Google Scholar
• Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699. Hypertension. 2010;56:831–838.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension. Circulation. 2011;124:1945–1955.
   PubMed Web of Science ®Google Scholar
• Karns AD, Bral JM, Hartman D, et al. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens. 2013;15:186–192.
   PubMed Web of Science ®Google Scholar
• Ménard J, Rigel DF, Watson C, et al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J Transl Med. 2014;12:340.
   PubMed Web of Science ®Google Scholar
• Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013;28:36–43.
   PubMed Web of Science ®Google Scholar
• FDA approves new treatment for adults with cushing’s disease | FDA [Internet]. 2020 Mar 06 cited 2021 Oct 27]. Available from 2021 Oct 27: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-cushings-disease.
   Google Scholar
• Duggan S. Osilodrostat: first Approval. Drugs. 2020;80:495–500.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferrigno R, and De Martino MC, et al. Medical treatment of Cushing’s disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne). 2020 Dec 8 ;11:648.
   PubMed Web of Science ®Google Scholar
• Meredith EL, Ksander G, Monovich LG, et al. Discovery and in vivo evaluation of potent dual CYP11B2 (Aldosterone synthase) and CYP11B1 Inhibitors. ACS Med Chem Lett. 2013;4:1203–1207.
   PubMed Web of Science ®Google Scholar
• Menard J, Watson C, Rebello S, et al. HORMONAL AND ELECTROLYTE RESPONSES TO THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN SODIUM DEPLETED HEALTHY SUBJECTS. J Am Coll Cardiol. 2010;55:A61.E583.
   Google Scholar
• Cuevas-Ramos D, Lim DST, Fleseriu M. Update on medical treatment for Cushing’s disease. Clin Diabetes Endocrinol. 2016;2:16.
   PubMedGoogle Scholar
• Bertagna X, Pivonello R, and Fleseriu M, et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99:1375–1383.
   PubMed Web of Science ®Google Scholar
• Creemers SG, Feelders RA, and de Jong FH, et al. Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of cushing syndrome: an in vitro study. J Clin Endocrinol Metab. 2019;104:3437–3449.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Fleseriu M, and Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020;8:748–761. .
   PubMed Web of Science ®Google Scholar
• Assessment report - Isturisa - European medicines agency [Internet]. 2019 cited 2021 Oct 27]. Abailable from 2021 Oct 27: https://www.ema.europa.eu/en/medicines/human/EPAR/isturisa
   Google Scholar
• Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome p450 enzymes in healthy adults. Clin Drug Investig. 2017;37:465–472.
   PubMed Web of Science ®Google Scholar
• Breitschaft A, Tauchmanova L, and Han K, et al. SAT-443 osilodrostat has no clinically relevant effect on the pharmacokinetic (PK) profile of a monophasic oral contraceptive in healthy females receiving cortisol replacement therapy. J Endocr Soc. 2019 Apr 15;3(Suppl 1):SAT–443. doi:https://doi.org/10.1210/js.2019-SAT-443.
   Google Scholar
• Tanaka T, Satoh F, Ujihara M, et al. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease. Endocr J. 2020;67:841–852.
   PubMed Web of Science ®Google Scholar
• Haissaguerre M, Puerto M, Nunes M-L, et al. Efficacy and tolerance of osilodrostat in patients with severe Cushing’s syndrome due to non-pituitary cancers. Eur J Endocrinol. 2020;183:L7–9.
   PubMed Web of Science ®Google Scholar
• Li L, Vashisht K, Boisclair J, et al. Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: a 13-week study in rats. Toxicol Appl Pharmacol. 2015;286:224–233.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Hatipoglu B, Molitch ME, et al. Osilodrostat can provide control of urinary free Cortisol for over 2.5 years in patients with Cushing’s disease: results from an extension to the linc-2 study [abstract no. OR22] The endocrine society’s 99th annual meeting and expo. Endocr Rev. 2017;38:i1–i1431.
   Google Scholar
• Pharmacokinetic (PK), pharmacodynamic (PD) and tolerability of osilodrostat in pediatric patients with Cushing’s disease - clinicaltrials.gov [Internet]. 2018 cited 2022 feb 13]. Available from 2022 feb 13: https://clinicaltrials.gov/ct2/show/NCT03708900
   Google Scholar
• Roll-over study in patients with endogenous Cushing’s syndrome for LCI699 - CLINICALTRIALS.gov [Internet]. 2018 cited 2022 feb 13]. Available from 2022 feb 13: https://clinicaltrials.gov/ct2/show/NCT03606408
   Google Scholar
• Efficacy and Safety Evaluation of Osilodrostat in Cushing’s Disease - ClinicalTrials.gov [Internet]. 2016 cited 2021 Oct 27]. Available from 2021 Oct 27: https://clinicaltrials.gov/ct2/show/NCT02697734.
   Google Scholar
• Pivonello R, Fleseriu M, and Newell-Price J, et al. Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: results from the LINC 3 study. Endocr Abstr. 2019;63: OC3.1. doi:https://doi.org/10.1530/endoabs.63.OC3.1.
   Google Scholar
• Castinetti F, Morange I, Jaquet P, et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol. 2008;158:91–99.
   PubMed Web of Science ®Google Scholar
• Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol. 2012;167:473–481.
   PubMed Web of Science ®Google Scholar
• Assié G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab. 2007;92:172–179.
   PubMed Web of Science ®Google Scholar
• Fontaine-Sylvestre C, Létourneau-Guillon L, Moumdjian RA, et al. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing’s disease. Pituitary. 2021;24:207–215.
   PubMed Web of Science ®Google Scholar
• Grossman AB. The molecular pathology of cushing disease: are we nearly there? J Endocr Soc. 2017;1:144–148.
   PubMed Web of Science ®Google Scholar
• Biller BM, Newell-Price J, and Fleseriu M, et al. OR16-2 osilodrostat treatment in cushing’s disease (CD): results from a Phase III, multicenter, double-blind, randomized withdrawal study (LINC 3). J Endocr Soc. 2019 Apr 15;3(Suppl 1): OR16–2. doi:https://doi.org/10.1210/js.2019-OR16-2
   Google Scholar
• Gadelha M, Bex M, Feelders RA, et al. Osilodrostat is an effective and well-tolerated treatment for Cushing’s disease (CD): results from a Phase III study with an upfront, randomized, double-blind, placebo-controlled phase (LINC 4). J Endocr Soc. 2021;5:A516–7.
   Google Scholar
• Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175:G1–34.
   PubMed Web of Science ®Google Scholar
• Debono M, Harrison RF, Chadarevian R, et al. Resetting the abnormal circadian cortisol rhythm in adrenal incidentaloma patients with mild autonomous cortisol secretion. J Clin Endocrinol Metab. 2017;102:3461–3469.
   PubMed Web of Science ®Google Scholar